What changed
$MCK — Distributes pharmaceuticals and provides healthcare services.
🎯 Q1 FY26 | Rev $96B | EPS $11.69 vs $11.57 🟢
💡 Consensus expects steady growth from McKesson's core distribution and U.S. Pharmaceutical segment, but the market may be underestimating the impact of GLP-1 drug distribution tailwinds and margin expansion from higher-margin specialty and oncology services.
🏢 Business Quality: 7/10 | Valuation: fair
📉 Reward/Risk: Upside 8% to $847 (consensus PT) vs downside 12% to $690 (support level); ratio ~0.67x, unfavorable for a long.
🔮 Catalyst: Next quarterly earnings (expected late July 2026) with focus on U.S. Pharmaceutical segment revenue growth and adjusted operating margin. Key metric: segment operating margin >2.6%. Failure signal: margin contraction or guidance below consensus.
Also in play: $MKC $CPB $SJM $K $CAG $AVY